5 Results
AIDS 2024: NIH Research Updates, Inequities, U=U, and Doxy PrEP (VIDEO)
The AIDS 2024 conference is taking place in Munich, Germany. HIV.gov is providing daily coverage.
Exploring a Meningitis Vaccine for Gonorrhea Prevention
A preventive vaccine for gonorrhea would be a major advance in public health, according to an editorial co-authored by NIAID Director Jeanne Marrazzo. The genetic sequences of the bacteria that cause gonorrhea and meningitis B, are closely related. This has led researchers to explore whether the 4CMenB vaccine, approved by the Food and Drug Administration for meningitis B, might also prevent gonorrhea. NIAID is sponsoring an efficacy study of the 4CMenB vaccine for gonorrhea prevention.
Sexually Transmitted Infections—A Closer Look at NIAID Research
Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites. NIAID supports research across the spectrum from basic to clinical science to develop effective diagnostic, preventive and therapeutic approaches to STIs in alignment with the National STI Strategic Plan. In recognition of National STI Awareness Week, NIAID shares a snapshot of new projects and recent scientific advances in STI research.
Doxy-PEP, HIV Vaccines and Community-Engaged Research: Discussions with Carl Dieffenbach and LaRon Nelson at CROI 2024 (VIDEO)
During the first full day of presentations at the 2024 Conference on Retroviruses and Opportunistic Infections, HIV.gov spoke with Carl Dieffenbach, Ph.D., director of NIAID’s Division of AIDS, and LaRon Nelson, Ph.D., R.N., F.N.P., F.N.A.P., F.N.Y.A.M., F.A.A., professor and associate dean at the Yale School of Nursing. They discussed Doxy-PEP for STI prevention, HIV vaccines, community engagement in research, and more. Watch their discussions.
Doxy-PEP for STIs and More—Dr. Dieffenbach’s Highlights from Day 1 of CROI 2023
During the first full day of research presentations at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), about some initial highlights, including the opening session that featured a lecture by Dr. Anthony Fauci and several studies about the use of doxycycline for post-exposure prophylaxis (Doxy-PEP) for sexually transmitted infections (STIs).